Which diabetes mellitus medicine given in which condition
The main diabetes medications and their indications, briefly:
- Metformin - first-line for Type 2 DM, especially in overweight/obese patients
- Sulfonylureas (glipizide, glibenclamide) - Type 2 DM when metformin is insufficient or contraindicated
- Insulin - Type 1 DM (mandatory), Type 2 DM when oral agents fail, gestational DM, DKA
- GLP-1 agonists (semaglutide) - Type 2 DM with cardiovascular disease or obesity
- SGLT2 inhibitors (empagliflozin) - Type 2 DM with heart failure or CKD
- DPP-4 inhibitors (sitagliptin) - Type 2 DM add-on, renal impairment-friendly
Searching sources...
Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Finding Sources
I have comprehensive data from Fuster & Hurst's The Heart (15th Edition) on diabetes pharmacotherapy. Let me now compose the full answer using this textbook data plus my knowledge.
Here is a complete, structured reference for diabetes mellitus medicines and their indications:
Diabetes Mellitus: Medicines and Their Conditions of Use
1. Biguanides - Metformin
| Drug | Brand | Condition / Indication |
|---|---|---|
| Metformin | Glucophage, Glumetza | 1st-line for Type 2 DM (T2D) - primary prevention and treatment |
| Glucophage XR | 2nd-line T2D - when additional control needed |
Key points:
- Drug of choice in overweight/obese T2D patients
- Reduces hepatic glucose output (gluconeogenesis)
- Dose with meals to reduce GI side effects
- Avoid if eGFR < 30 mL/min (hold on surgery day)
- Avoid excess alcohol use
- NOT used in Type 1 DM as primary therapy
2. SGLT2 Inhibitors (Sodium-Glucose Co-Transporter 2 Inhibitors)
| Drug | Brand | Condition / Indication |
|---|---|---|
| Canagliflozin | Invokana | 2nd-line T2D; 1st-line T2D + CVD / Heart Failure / Microalbuminuria |
| Empagliflozin | Jardiance | 2nd-line T2D; 1st-line T2D + CVD / Heart Failure / Microalbuminuria |
| Dapagliflozin | Farxiga | 2nd-line T2D |
| Ertugliflozin | Steglatro | 2nd-line T2D |
Key points:
- Block glucose reabsorption in kidney - glucose lost in urine
- Preferred when T2D is complicated by cardiovascular disease, heart failure, or proteinuric CKD
- Hold for eGFR < 30 mL/min (Ertugliflozin: hold < 60 mL/min)
- Can cause euglycemic DKA - stop before surgery
- HbA1c reduction: 0.5-1.0%
3. GLP-1 Receptor Agonists (Glucagon-Like Peptide-1)
| Drug | Brand | Condition / Indication |
|---|---|---|
| Exenatide | Byetta | 2nd-line T2D; 1st-line T2D + CVD / Obesity / High TG |
| Exenatide XR | Bydureon | 2nd-line T2D; 1st-line T2D + CVD/Obesity/High TG |
| Liraglutide | Victoza | 2nd-line T2D; 1st-line T2D + CVD/Obesity |
| Semaglutide | Ozempic | 2nd-line T2D; 1st-line T2D + CVD / Obesity |
| Dulaglutide | Trulicity | 2nd-line T2D |
Key points:
- Injectable (subcutaneous) agents - stimulate insulin secretion in glucose-dependent manner
- Preferred when T2D is complicated by obesity, cardiovascular disease, or high triglycerides
- Significant weight loss benefit (1-5 kg)
- HbA1c reduction: 1.0-1.5%
- Hold Exenatide if eGFR < 30 mL/min
4. DPP-4 Inhibitors (Dipeptidyl Peptidase-4 Inhibitors / "Gliptins")
| Drug | Brand | Condition / Indication |
|---|---|---|
| Sitagliptin | Januvia | 2nd-line T2D; safe in renal impairment (dose-adjusted) |
| Saxagliptin | Onglyza | 2nd-line T2D |
| Linagliptin | Tradjenta | 2nd-line T2D; no renal dose adjustment needed |
| Alogliptin | Nesina | 2nd-line T2D |
Key points:
- Oral agents, well-tolerated, weight neutral
- Prevent breakdown of endogenous GLP-1
- Useful in elderly patients and those with renal impairment (especially Linagliptin)
- HbA1c reduction: 0.5-0.8%
5. Sulfonylureas (SU)
| Drug | Brand | Condition / Indication |
|---|---|---|
| Glipizide | Glucotrol | 2nd-line T2D; especially when cost is a concern |
| Glimepiride | Amaryl | 2nd-line T2D |
| Glyburide | DiaBeta | 2nd-line T2D (avoid in elderly - long half-life) |
Key points:
- Stimulate pancreatic beta cells to secrete insulin
- Useful when HbA1c reduction > 1% is needed quickly
- Risk of hypoglycemia and weight gain
- Avoid in renal failure (accumulation risk)
- Low cost - preferred in resource-limited settings
- HbA1c reduction: 1.0-1.5%
6. Thiazolidinediones (TZDs / "Glitazones")
| Drug | Brand | Condition / Indication |
|---|---|---|
| Pioglitazone | Actos | 2nd-line T2D; T2D with insulin resistance |
| Rosiglitazone | Avandia | 2nd-line T2D (restricted use - CV concerns) |
Key points:
- Insulin sensitizers - act via PPAR-gamma receptors
- Useful in T2D with significant insulin resistance
- Avoid in heart failure (cause fluid retention)
- Risk of bone fractures and weight gain
- HbA1c reduction: 0.8-1.0%
7. Meglitinides / Glinides
| Drug | Brand | Condition / Indication |
|---|---|---|
| Repaglinide | Prandin | T2D with irregular meal patterns |
| Nateglinide | Starlix | T2D with postprandial hyperglycemia |
Key points:
- Short-acting insulin secretagogues - taken just before meals
- Ideal for patients with erratic schedules
- Less hypoglycemia risk than sulfonylureas
- HbA1c reduction: 0.5-1.0%
8. Alpha-Glucosidase Inhibitors
| Drug | Brand | Condition / Indication |
|---|---|---|
| Acarbose | Precose | T2D with postprandial hyperglycemia; pre-diabetes |
| Miglitol | Glyset | T2D; postprandial control |
Key points:
- Delay carbohydrate digestion in intestine
- Reduce post-meal glucose spikes
- GI side effects (flatulence, diarrhea) limit use
- HbA1c reduction: 0.5-0.8%
9. Insulin - Conditions of Use
| Condition | Type of Insulin Used |
|---|---|
| Type 1 DM (mandatory) | Basal-bolus regimen: long-acting (Glargine/Detemir) + rapid-acting (Lispro/Aspart) |
| Type 2 DM - oral agents failed | Add basal insulin first (Glargine/Detemir), then bolus |
| Gestational DM | Short-acting/intermediate insulin (NPH + Regular) |
| DKA / HHS | IV continuous insulin drip (Regular insulin); lower BG ~100 mg/dL/hr |
| Inpatient/Hospitalized DM | Insulin preferred over oral agents for all DM types |
| Perioperative period | 60-80% of usual basal dose; hold oral agents on surgery day |
| Critically ill patients | IV insulin drip; target glucose 80-180 mg/dL (ICU) |
Insulin types by duration:
| Type | Example | Onset | Duration | Use |
|---|---|---|---|---|
| Rapid-acting | Lispro, Aspart, Glulisine | 5-15 min | 3-5 hr | Mealtime bolus |
| Short-acting | Regular | 30-60 min | 5-8 hr | Meals, DKA drip |
| Intermediate | NPH | 2-4 hr | 12-18 hr | Twice-daily regimens |
| Long-acting | Glargine, Detemir | 1-2 hr | 20-24 hr | Basal once daily |
| Ultra-long | Degludec | 1-2 hr | >42 hr | Flexible dosing |
10. Special Populations - Quick Summary
| Population | Preferred Agent(s) | Avoid |
|---|---|---|
| Obesity | GLP-1 agonists, SGLT2i | Sulfonylureas, TZDs (weight gain) |
| Heart failure | SGLT2i (Empagliflozin) | TZDs, Saxagliptin |
| CKD / Renal impairment | Linagliptin, Insulin | Metformin (eGFR<30), SGLT2i (eGFR<30), Sulfonylureas |
| CVD (atherosclerosis) | GLP-1 agonists, SGLT2i | - |
| Elderly | DPP-4i, Linagliptin, short-acting insulin | Glyburide (long-acting SU) |
| Pregnancy / Gestational DM | Insulin (1st choice), Metformin | All others |
| DKA | IV Insulin drip | All oral agents |
| Type 1 DM | Insulin (mandatory) | Oral agents alone |
Summary Flowchart: T2D Management
Newly diagnosed T2D
|
v
Lifestyle + Metformin (1st line)
|
v
HbA1c not at goal after 3 months?
|
├─ + CVD/HF/CKD → Add SGLT2i or GLP-1 agonist
├─ + Obesity → Add GLP-1 agonist (weight loss)
├─ + Cost concern → Add Sulfonylurea
└─ General → Add DPP-4i or SGLT2i
|
v
Still not at goal → Triple therapy or Add Insulin
Sources: Fuster & Hurst's The Heart, 15th Edition (Table 7-5: Diabetes Pharmacotherapy); Harrison's Principles of Internal Medicine, 22nd Edition (2025)
This is a shared conversation. Sign in to Orris to start your own chat.